"Morocco Pharmaceuticals & Healthcare Report Q1 2016" is now available at Fast Market Research

The Moroccan government's decision to reimburse generic Sovaldi (sofosbuvir) along with the incorporation of students into it medical coverage scheme highlights its commitment to increasing the population's access to healthcare - a positive to drugmakers. However, in the long-term, the uncertainty surrounding drug prices will still remain an issue for drugmakers, hindering the country's attractiveness to drug companies whose portfolios contain high value drugs.

Headline Expenditure Projections

Pharmaceuticals: MAD12.52bn (USD1.49bn) in 2014 to MAD13.39bn (USD1.40bn) in 2015; +6.8% in local currency terms and -5.9% in US dollar terms. Forecast revised upwards from last quarter.
Healthcare: MAD55.63bn (USD6.61bn) in 2014 to MAD59.35bn (USD6.21bn) in 2015; +6.7% in local currency terms and -6.1% in US dollar terms. Forecast revised downwards from last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1109905_morocco_pharmaceuticals.aspx?afid=302

Risk/Reward Index

The Morocco Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Morocco pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Morocco, to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
* Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

* Healthcare:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016